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Available online 27 July 2016Aims:Device-based remotemonitoring (RM) has been linked to improved clinical outcomes at short tomedium-
term follow-up.Whether this beneﬁt extends to long-term follow-up is unknown.We sought to assess the effect
of device-based RMon long-term clinical outcomes in recipients of implantable cardioverter-deﬁbrillators (ICD).
Methods:We performed a retrospective cohort study of consecutive patients who underwent ICD implantation
for primary prevention. RM was initiated with patient consent according to availability of RM hardware at im-
plantation. Patients with concomitant cardiac resynchronization therapy were excluded. Data on hospitaliza-
tions, mortality and cause of death were systematically assessed using a nationwide healthcare platform. A
Cox proportional hazards model was employed to estimate the effect of RM on mortality and a composite end-
point of cardiovascular mortality and hospital admission due to heart failure (HF).
Results: 312 patients were included with a median follow-up of 37.7 months (range 1 to 146). 121 patients
(38.2%) were under RM since the ﬁrst outpatient visit post-ICD and 191 were in conventional follow-up. No
differenceswere found regarding age, left ventricular ejection fraction, heart failure etiology or NYHA class at im-
plantation. Patients under RM had higher long-term survival (hazard ratio [HR] 0.50, CI 0.27–0.93, p = 0.029)
and lower incidence of the composite outcome (HR 0.47, CI 0.27–0.82, p = 0.008). After multivariate survival
analysis, overall survival was independently associated with younger age, higher LVEF, NYHA class lower than
3 and RM.
Conclusion: RM was independently associated with increased long-term survival and a lower incidence of a
composite endpoint of hospitalization for HF or cardiovascular mortality.
© 2016 Elsevier Ireland Ltd. All rights reserved.Keywords:
Remote monitoring
ICD1. Introduction
Technological developments and expanded indications have
translated into a large population of recipients of implantable electronic
cardiac devices. There has been a signiﬁcant increase in the number of
patients submitted to implantation of cardioverter-deﬁbrillators (ICD).
This growing population represents a unique challenge regarding their
follow-up, requiring an experienced team with in-depth knowledge of
device programming and potential complications [1]. To this date,
optimal clinical resource allocation regarding adequate follow-up to
these patients is not yet established.
In this setting, remote monitoring (RM) is poised as an optimal tool
in the intensive and continuous follow-up of ICD patients. Published
data supports the safety and efﬁcacy of this intervention [1]. However,ospital de Santa Marta, Rua de
eliability and freedom from bias
.
ded from ClinicalKey.com at Centr
only. No other uses without permissdata regarding potential clinical beneﬁts has been scarce, with a short
duration of follow-up and mainly limited to speciﬁc ICD brands.
In this studywe aimed to assess the long-term clinical beneﬁts of RM
in a population of patients with ICD for primary prevention of sudden
cardiac death. As such, we sought to investigate the effect of RM on
hospital admissions for heart failure (HF), cardiovascular death and
all-cause death.
2. Methods
Weperformed a retrospective cohort study in patients who underwent ICD implanta-
tion for primary prevention and compared a group followedwith use of RM (RM+)versus
a group on conventional outpatient clinic follow-up (RM−). Consecutive patients referred
to a tertiary center for implantation of an ICD between December 2002 and October 2014
were included. The study populationwas divided in two groups, according to themodality
of follow-up: RM+ versus RM−. The protocol was approved by the Ethics Committee of
our institution.
Implantation of an ICD was performed according to international guidelines [2]
regarding patients with systolic dysfunction or primary channelopathies. ICD implan-
tation in the setting of hypertrophic cardiomyopathy was performed according to
disease-speciﬁc guidelines [3]. Patients with indication for implantation for
secondary prevention or with concurrent implantation of cardiac resynchronizationo Hospitalar Lisboa Central August 16, 2016.






Number 121 (38.2%) 191 (61.8%)
Age at implantation (years) 56.9 +/− 1.3 57.9 +/− 1.1 NS
Male sex 104 (85.9%) 170 (89.0%) NS
Left ventricular ejection fraction (%) 30.0 +/− 1.14 28.2 +/− 0.69 NS
Etiology NS
• Ischaemic 66 (54.5%) 117 (61.2%)
• Dilated cardiomyopathy 35 (28.9%) 51 (26.7%)
• Hypertrophic cardiomyopathy 11 (9.1%) 14 (7.3%)
• Brugada syndrome 4 (3.3%) 6 (3.1%)
• Other 6 (4.9%) 3 (1.5%)
NYHA class
I 24 (19.8%) 31 (16.2%)
II 79 (65.3%) 133 (69.6%)
III 17 (14.0%) 26 (13.6%)
IV 1 (0.8%) 1 (0.5%)
Device Brand b0.001
• Biotronik 58 (78.4%) 16 (21.6%)
• Boston Scientiﬁc 25 (31.6%) 54 (68.3%)
• Medtronic 25 (34.7%) 47 (65.3%)
• Sorin 11 (19.3%) 46 (80.7%)
• St- Jude Medical 2 (5.9%) 32 (94.1%)
765G. Portugal et al. / International Journal of Cardiology 222 (2016) 764–768therapy (CRT) were excluded. ICD patients who underwent an upgrade to a CRT
system during follow-up were censored for analysis after the procedure.
RM was offered to patients whenever available as offered by the device company,
with patient informed consent. The equipment was provided free of charge at the ﬁrst
outpatient visit after ICD implantation. Patients were then scheduled for a hospital visit
every 12months, with transmissions performed every 3months, during the study period.
Reports were reviewed by trained technicianswhowould alert the attending physician in
case of relevant events. Additionally, RM alerts were transmitted in response to abnormal
events such as delivered shocks, detection of atrial ﬁbrillation episodes or abnormal values
of the various ICD parameters. In this case, patients were summoned in the following 48 h
for an in-person consultationwith an electrophysiologist in order to reviewof the episode.
Conventional follow-up consisted of a patient visit 1 month after implantation and
every 4 months thereafter. Device interrogation was performed in all visits, and relevant
events (e.g. lead impedance or other parameters changes, atrial ﬁbrillation detection or
appropriate/inappropriate therapy) were registered. The patient was then observed by
an electrophysiologist, and changes in device programming, reintervention, drug therapy
or indication for ablation were employed as deemed appropriate.
Data collection regarding arrhythmic events, device programming and appropriate
and inappropriate therapy via ICD was prospectively inputted into a database consisting
of all patients. These records were then assessed at the time of this study for possible
missing data and completed whenever possible. Patients were considered lost to
follow-upwhen the last outpatient visit was N18monthswith no further scheduled visits.
Information on hospitalizations and mortality was assessed with the use of a nation-
wide healthcare platform (“Plataforma deDados de Saúde”) integrating records of 9 out of
10 of the referring hospitals and the National Registry on Mortality. Patient records were
systematically reviewed, and information was collected regarding hospital admissions
and all-cause mortality. The cause of hospitalization was determined according to an
International Classiﬁcation of Disease-9 (ICD-9) based system as coded by the discharging
hospital. Likewise, cause of mortality was determined according to the same ICD-9 based
codiﬁcation. Thephysician responsible for assessing study outcomeswas blinded in regard
to the modality of follow-up (remote monitoring vs in-ofﬁce).
The main measured endpoint was time to all-cause death. A secondary endpoint
consisted of a composite endpoint of time to hospitalization for HF or cardiovascular
death. In addition, we determined independent predictors of time to all-cause death
with use of a stepwise approach.
3. Statistical analysis
Continuous variables were displayed as mean and standard devia-
tion where they followed a normal distribution, and in terms of their
median and interquartile range where they did not. Qualitative
variables were expressed in terms of frequency and percentage.
Baseline comparisons were performed using the chi-square test for
qualitative data and the t-student test for continuous variables.
The analysis of main outcome of time to admission for HF and
mortality was performed by Kaplan–Meier curves, log-rank test for
comparisons and use of the Cox proportional hazardsmodel for calcula-
tion of the hazard ratio (HR). A stepwise approach was employed to
determine independent predictors of all-cause death. Initially, univari-
ate predictors of all-cause death were determined with use of a Cox
regression model. Variables with a signiﬁcance level b 0.1 were subse-
quently included in the multivariate survival model. We additionally
performed subgroup analysis for age, left ventricular ejection fraction,
etiology and device brand. A two-sided P-value b 0.05 was considered
statistically signiﬁcant. All statistical analysis was performed with the
software package STATA 12 (Statacorp).
4. Results
4.1. Study population
A total of 923 patients received an ICD during this period. Of these,
611 patients were excluded on the basis of concomitant CRT (473
patients) or implantation in the setting of secondary prevention
(138 patients). After exclusion, a total of 312 patients underwent
further analysis.
Patient characteristics at implantation are described in Table 1. Most
patients had an indication for ICD in primary prevention in the setting of
left ventricular systolic dysfunction (85.6%). The etiology was ischemic
cardiomyopathy in 58.5%, idiopathic dilated cardiomyopathy in 27.1%,
hypertrophic cardiomyopathy in 8.1%, Brugada syndrome in 3.3% and
other etiologies in 3.0% (4 patients with hypertensive heart disease, 2Downloaded from ClinicalKey.com at Centro Ho
For personal use only. No other uses without permission. Cpatients with congenital heart disease, 2 patients with valvular heart
disease and 1 patients with left ventricle non-compacted
cardiomyopathy).
After stratiﬁcation for RM, 121 patients were under remotemonitor-
ing (RM+, 38.2%) and 191 on conventional follow-up (RM−, 61.8%).
The mean ejection fraction was 28.9%, with no difference between
groups regarding left ventricular systolic function (LVEF, 30.0% +/−
1.14 vs. 28.2 +/− 0.69%, p = NS). No signiﬁcant differences were
found regarding age at implantation (RM vs. controls; 56.9 +/− 1.3
vs. 57.9 +/− 1.1 yrs., p = NS).
4.2. Follow-up
Median follow-up was 37.7 months (IQR 18.8–65.8), with 4
patients (1.28%) lost to follow-up during the 12 year study period
(1 in the RM+ group and 3 in the RM− group, p = NS). Mean
follow-up durationwas higher in patients under RM (48.4months+/−
2.7 vs 40.3+/− 2.2, p= 0.021). Data on overall mortality was available
for the remaining 307 patients, and was used to calculate the
Kaplan–Meier survival estimates (Fig. 1).
4.3. Primary outcome
Regarding overall mortality, RM was signiﬁcantly associated with
increased survival with a hazard ratio of 0.51 (Conﬁdence interval
0.24–0.84, p = 0.021). This difference, manifested early during follow-
up and increased throughout the study time, suggests a cumulative
beneﬁt of RM with length of follow-up.
In addition, we performed a stepwise multivariate analysis for
determination of independent predictors of survival at follow-up,
which showed that lower age, higher LVEF, NYHA functional class b3
and RM were independent predictors of survival (Table 2).
To test whether increased availability of RM on recent years could
explain the improved outcomes in these patients, we controlled for
the effect of year of implantation by patients into quartiles according
to year of implantation. We found no effect of implantation year on
overall survival (Cox regression, HR 0.99, CI 0.99–1.00, p = 0.557) nor
was the effect of RM on mortality inﬂuenced by year of device
implantation (p for interaction = 0.744).
The results for the subgroup analysis are presented in Fig. 2. No
statistically signiﬁcant differences were found regarding the effect of
RM on mortality when stratifying by LVEF, age, etiology or devicespitalar Lisboa Central August 16, 2016.
opyright ©2016. Elsevier Inc. All rights reserved.
Fig. 1. Kaplan–Meier plot of overall mortality after stratiﬁcation for remotemonitoring. Of
note, a survival beneﬁt is noted early on and is consistent throughout the duration of
follow-up.
766 G. Portugal et al. / International Journal of Cardiology 222 (2016) 764–768brand (p = NS for all). However, a non-signiﬁcant trend was observed
suggesting a greater beneﬁt of RM in patients aged older than
60 years, with LVEF b 30% and with an ischemic etiology.
4.4. Secondary outcome
There were a total of 121 events during this period, consisting of 63
admissions for HF and 58 deaths, of which 30 were deemed to be of
cardiovascular causes. These 93 events (63 admissions due to HF and
30 cardiovascular deaths) corresponded to the secondary outcome,
which was observed in 17 patients in the RM group and in 48 patients
in the conventional follow-up group (p = 0.021). Kaplan–Meier plots
for the composite outcome of cardiovascular death or hospitalization
for HF are plotted on Fig. 3. RM was associated with a hazard ratio of
0.47 for this composite outcome (CI 0.27–0.82, p = 0.008).
5. Discussion
The main ﬁnding of our study was a signiﬁcantly lower incidence of
unplanned hospital admissions for HF and overallmortality at very-long
follow-up in patients under RM. This reduction in mortality wasmainly
driven by a reduction in cardiovascular mortality.
To further validate our ﬁndings and adjust for the potential con-
founding effect of other baseline characteristics, we used a stepwise
approach to calculate a multivariate Cox regression model performed
a multivariate regression analysis, which consistently showed theTable 2
Survival analysis.
Univariate analysis p= Multivariate model p=
Age HR 1.06
CI 1.03–1.09
b0.001 HR 1.07 CI 1.04–1.10 b0.001







0.003 HR 0.95 CI 0.91–0.99 0.028
NYHA class N II HR 2.16 CI 1.11–4.19 0.023 HR 2.52 CI 1.27–4.99 0.008
Remote monitoring HR 0.51 CI 0.28–0.90 0.021 HR 0.50 CI 0.27–0.93 0.029
Device brand
Biotronik HR 0.94 CI 0.50–1.75 0.842
Boston Scientiﬁc HR 1.10 CI 0.61–1.97 0.33
Medtronic HR 0.71 CI 0.36–1.43 0.347
Sorin HR 1.67 CI 0.89–3.12 0.109
St- Jude Medical §
§ Statistical analysis not performedowing to lownumber of patients on remotemonitoring.
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our cohort, RM was an independent predictor of lower mortality
at follow-up.
The beneﬁt of RMwas consistent across all tested device brands. We
also did not detect a signiﬁcant difference on the beneﬁt of RMby sever-
ity of LV dysfunction, age or etiology. Although this study was not
adequately powered to detect differences between subgroups, we did
ﬁnd a non-signiﬁcant trend toward a larger reduction in mortality in
higher risk patients (LVEF b 30%, age over 60 years, ischemic etiology),
suggesting that these patients may derive the most beneﬁt from this
technology.
Our study cohort consisted of unselected, all-comers with indication
for ICD implantation for primary prevention of sudden cardiac death. As
previously stated, there was no formal randomization of patients, with
RM instituted according to an independent external factor, in this case
the availability of the remote monitoring hardware as offered by the
device company. This in effect led to a quasi-randomized patient
allocation, with well balanced baseline patient characteristics and no
signiﬁcant differences between groups.
Data was available on hospital admissions or mortality for 98.72% of
our cohort, and cause of death or hospitalization was assessed as
previously mentioned in the Methods section. Patients were followed
for up to 12 years with a consistent beneﬁt of RM across the duration
of follow-up.
Contemporary wireless RM systems forgo the need for manual
wanded transmissions and perform automatic transmissions requiring
minimal patient input. Notwithstanding, recognized gains in resource
efﬁciency, and some clinical beneﬁts have also been demonstrated in
clinical trials. These included a greater adherence to follow-up and a
faster time to physician evaluation after event occurrence [4], and also
lower incidence of atrial ﬁbrillation and stroke related hospital admis-
sions [5], and reduced length of hospital stay (ref). However, most stud-
ies on RM were underpowered to effectively assess clinical outcomes,
either due to a low number of recruited patients or short duration of
follow-up.
Recently, the PREDICT-RM trial demonstrated not only a reduction
in all-cause rehospitalizations, but also in all-cause mortality in a large
cohort of patients after newly ICD implantation who underwent
RM during follow-up [6]. In the IN-TIME study, Hindricks, et al. [7] ran-
domized 716patientswith left ventricular dysfunction submitted to im-
plantation of an ICD (with or without CRT) to automatic, daily, implant-
based telemonitoring versus conventional follow-up in a single-blinded
design. After 1 year, patients under RM had a lower composite score of
all-causemortality, admission for HF, change in NYHA class, and patient
global self-assessment. The secondary outcome of all-cause death was
signiﬁcantly lower in the RM group (10 vs. 27 patients).
The ALTITUDE Survival Study [8], a registry-based study which
assessed the long-term survival of 194,006 ICD and CRT recipients of
Boston intra-cardiac devices. Patients who were under RM follow-up
with transmission of information to the LATITUDE network had signiﬁ-
cantly improved long-term survival, with a 50% relative risk reduction
on overall mortality (HR 0.56 for ICD recipients; HR 0.45 for CRT
recipients). Also, the recently published EFFECT trial [9], a prospective,
observational trial of RM in patients submitted to an ICD-CRT implanta-
tion, also showed an improvement in the combined endpoint of death
or cardiovascular hospitalization.
Not all studies on the effect of RM on mortality have been positive.
The TELE-HF trial [10] randomized 1653 high-risk patients to phone
call telemonitoring or conventional follow-up. The main outcome of
all-causemortality or rehospitalization at 180 dayswas not signiﬁcantly
improved. However, the adherence and frequency of use of RM may
have a signiﬁcant impact on its clinical effect. A recently published sys-
tematic review and meta-analysis [11] of clinical outcomes in random-
ized controlled trials of RM vs. conventional follow up showed that a
survival beneﬁt was observed (OR: 0.65; p = 0.021) only in the subset
of 3 RCTs with daily veriﬁcation of transmission, as is performed in ourHospitalar Lisboa Central August 16, 2016.
. Copyright ©2016. Elsevier Inc. All rights reserved.
Fig. 2. Subgroup analysis for effect of RM on mortality.
767G. Portugal et al. / International Journal of Cardiology 222 (2016) 764–768center. In addition, a graded relationship between adherence to RM and
improved survival was observed in a recent big data study of 269,471
implants by Varma, et al. [12].
In our study, patients with concomitant CRT were excluded. This
population could conceivably have a similar or larger clinical beneﬁt
from RM, owning to the added complexity of their outpatient manage-
ment. However, the effect of CRTon disease history and the variability in
echocardiographic and clinical responses to CRT would make it more
difﬁcult to ascertain the exact effect of RM in these patients. In our
study, patients who were subsequently upgraded to an ICD-CRT were
censored from analysis after the procedure to exclude a potential
confounding effect.
While the magnitude of the effect of RM onmortality in our study is
surprising, it is similar to previous reports such as the IN-TIME study
and the ALTITUDE survival registry. Suggestedmechanisms for themor-
tality beneﬁt observed with RM include earlier notiﬁcation of adverse
events, increased patient involvement in his own healthcare, and aFig. 3. Kaplan–Meier plot of incidence of cardiovascular death or hospitalization for
heart failure.
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status for each patient. In any case, our data supports the notion that
RM is certainly not harmful, and may have a beneﬁcial and long-term
impact on overall mortality, which appears to stem mainly from lower
cardiovascular mortality and a reduction in the incidence of hospitaliza-
tions for HF, a well recognized adverse prognostic factor.6. Limitations
This was a single center non-randomized study, thus the generaliz-
ability of our results is limited. As this is a retrospective cohort trial,
we cannot exclude the effect of unmeasured confounders or some de-
gree of bias; in particular, despite there being no signiﬁcant differences
between both groups at baseline, we cannot exclude the effect of poten-
tial selection bias. In addition, since patients had to agree to the use of
RM, we could hypothesize that some of those who refused RM had
also less adherence to other measures (i.e. medication), which could
make RM a surrogate for non-compliance. However, measured patient
characteristics were well balanced between groups at baseline, and
the magnitude and temporal consistency of the clinical beneﬁt on the
RM group suggests a more signiﬁcant effect that what would be ex-
plained by a lower compliance. In addition, the use of “hard” endpoints
(hospitalization or death) and the employment of a publicly available
database reduce the possibility of underreporting of events in the
conventional follow-up group as compared to the RM group.7. Conclusions
In this very long-term retrospective cohort study, the use of RM in
patients submitted to implantation of an ICD for primary prevention
was independently associated with increased survival. RM was also
associated with a lower incidence of a composite endpoint of hospitali-
zation for HF or cardiovascular mortality. Larger, adequately powered
randomized clinical trials are warranted to deﬁnitely establish whether
device-based remotemonitoring can lead to improved outcomes in this
high-risk population.spitalar Lisboa Central August 16, 2016.
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